ALSO NOTED: Galapagos gains development grants;Aastrom to sell stock; and much more...

> Galapagos has garnered €5.2 million in grant money to continue its drug development work. Release

> Aastrom Biosciences is raises $13.5 million in a stock offering. Release

> Chutes & Ladders: Fresh from raising $35 million from a Series B of venture capital, Metastatix has named Carol Gallagher as its new president and CEO. Release (.pdf)

> BioSynthema has inked a deal to use Covidien technology to develop a new, targeted radionuclide therapy product. Release

> Boston Scientific is poised to join its healthcare colleagues in laying off thousands of workers. Report

> Last week, the buzz about GlaxoSmithKline's CEO-presumptive Andrew Witty included worries that his internal competitors for the top slot would jump ship. Now Glaxo may sweeten the pot for those also-rans--by putting them on the board of directors. Report

> Here's Exhibit Z in the long list of reasons why Big Pharma wants to make deals with biotech--and why speculation about Biogen and Genzyme is running so high. Roche and Genentech are both reaping a big harvest from their joint cancer drugs this quarter. Report

> Low doses of a human antibody in mice were effective in repairing damaged myelin, a protective shield for nerves that is destroyed by multiple sclerosis. Report

And Finally... Who is most likely to buy Biogen Idec? Poll

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.